Authors

Actionable Insights at the Point of Care: A New Era in Provider Engagement

How pharma marketers can time brand messages to prescribers when it matters most.

When Friction Meets Force in Clinical Research

Special Guest Op-Ed: What a decade of collaboration and shared effort reveals about the future of drug development.

Bridging the Data Gap: How Digital Behavioral Insights Can Transform HCP Targeting in Specialty Care

As therapeutic complexity increases, life sciences companies should cultivate open mindsets toward innovative data sources beyond traditional claims and electronic medical record data.

Bets and Balances: Riding the Risk-and-Innovation Pendulum in Biotech

Ken Banta and Andrew Hall share insights on leading through uncertainty—covering culture, capital, risk, and the regulatory headwinds influencing key decisions in drug development.

Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for Executives

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

From Sun Belt Boom to Biotech Hub: Why Southern Florida’s Moment has Arrived

Greater Miami is rapidly emerging as an international biotech hot spot—as capital, talent, and infrastructure converge to transform the region from a tourism-driven economy into a globally connected life sciences innovation hub.

Point of Care Lifts Reps Efforts

Point of Care and PatientPoint can improve the impact that your Pharma Reps are already having.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

The End of the Rebate Era? What HR Leaders and Pharmacy Consultants Need to Know About Biosimilars

As the availability and utilization of ultra-high-cost, long-term specialty products such as GLP-1s and cell and gene therapies grows, HR decision-makers and pharmacy consultants must embrace a more value-oriented mindset where they can.

2025 Pharma Forecast: Four Pivotal Trends Revolutionizing Market Access Strategies

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

A Brave New World: Implications of the IRA on Brand Strategy

Amid converging pharma pricing trends, such as those triggered by the Inflation Reduction Act, companies must adopt novel operational practices and strategic approaches in line with new parameters for success across a product’s lifecycle.

The Evolution of Healthcare Communication: Bridging the HCP-Patient Divide

Key trends in healthcare communication to build trust between healthcare providers and their patients.

The AI Force Multiplier: How AI Is Leveling the Playing Field for Small and Mid-Size Biotech

By giving small and mid-size biotechs access to real-world data and advanced analytics once reserved for large pharma, AI platforms are leveling the playing field by enabling lean teams to de-risk clinical strategy, strengthen fundraising narratives, and make faster, more confident decisions across the development lifecycle.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Strategic advantage: Optichannel engagement drives ROI across the product lifecycle

Your Phase III Clinical Protocol Is Your Initial Product Launch

How demand-driven development will help new products be more successful.

Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint

Recent policy shifts in these two influential health technology assessment markets signal a broader regional move toward faster, more innovation-friendly access frameworks.

Navigating Cross-Border Pharma Deals: Key Trends and Lessons Out of China

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Transforming Life Sciences R&D: The Business Case for AI

Webinar Date/Time: Thu, Aug 14, 2025 3:30 PM EDT

JCA vs. Reality: Europe’s Push for Clinical Harmonization

Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.

Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for Executives

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

Taking Advantage of ‘Hidden Gem’ Talent Hubs

How to optimize a pharma location strategy in unheralded but rich regions for biotech talent around the world.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Navigating the EU’s Joint Clinical Assessment

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be critical.

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

Pharma Forecasting: Key Markets Investors Can’t Ignore

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Driving Field Excellence with AI-Enhanced Rep Support